(From left) Sun Pharmaceutical Industries CFO C S Muralidharan, and CEO, India business, Kirti Ganorkar
After posting a 43 per cent rise in Q1 profit after tax (PAT) and 29 per cent jump in sales of specialty products, Sun Pharma is now eyeing to commercialise its specialty products basket in countries outside the US. Speaking to Sohini Das, Sun Pharmaceutical Industries chief financial officer (CFO) C S Muralidharan and chief executive officer (CEO), India business, Kirti Ganorkar, talk about future plans and the incremental innovation in products that they plan to bring to India. Edited excerpts:
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.